← Back

Wire · operational-macro

First factor XIa inhibitor nabs FDA approval for stroke prevention

Published

11 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at nature.com →

◆ Verified

Fusion42 · 12 November 2026 · Fusion42 review

The US FDA has approved Bayer's asundexian (Sunharbo), the first factor XIa inhibitor, for stroke prevention in patients with recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Asundexian is used alongside antiplatelet therapy and works by reducing pathological clot formation.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You face a newly approved stroke prevention drug that changes the anticoagulant market rules. Your biotech or medtech startup must evaluate this competitor's mechanism and timing to adjust development or partnerships.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalstroke-preventionanticoagulantbayerfactor-xia